PDCD1 and neoplasm: The antitumor effects of immune checkpoint inhibitors (ICIs), antibodies, that block PD-1 or PD-L1, were found to be enhanced by redirecting the function of tumor-associated macrophages, the NK cell-DC axis in the tumor environment [146,147].